Now Enrolling

J2W-MC-PYAB

...

A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of neutralizing antibody bamlanivimab (LY-COV555) in Participants with Mild to Moderate COVID-19 Illness following protocals LY3819253, LY3832479 and other study arms (patients must have a positive COVID-19 nasal swab test within 72 hours of enrolling)

Read More at Lilly
Read More
Read More

Top of Page

GS-US-200-4334

...

A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV

Read More
Read More

Top of Page

GS-US-200-4625

...

A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS-6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance

Read More
Read More

Top of Page

CP101

Finch Therapeutics

A Phase III Clinical Trial Studying CP101 for Recurrent C. Difficile, With a Rollover Open-Label Option.

Read More at Finch Therapeutics
Read More
Read More

Top of Page

IIT-2017-10117

...

A pilot study for Allergan's intravenous antibiotic, Dalvance® (dalbavancin), administered every 14 days for the treatment of Septic Arthritis (2 infusions) and / or Osteomyelitis (3 infusions)
Read More at Contagion Live
Read More at ClinicalTrials.gov
Read More at Contagion Live
Read More at Oxford Academic

Top of Page

Closed to Enrollment

C4591001

...

A phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, Immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals.

Read more at Pfizer News
Read More at Medical Xpress
Read More at Clinical Trails Arena

Updated General Eligibility Criteria
Informed Consent Disclosure

Top of Page

B5091007

...

A Phase 3, Placebo-controlled, Randomized, Observer-blinded Study to Evaluate the Efficacy, Safety, and Tolerability of a Clostridium Difficile Vaccine In Adults 50 Years of Age and Older

Read More
Read More at Clover Trial

Top of Page

ViiV 209035

...

ViiV 209035 - This is a “roll-over” study including only current patients from another trial: A Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-1 infected Adults who are Virologically Suppressed and Participated in Study LAI116482

Top of Page

ViiV 207966

...

207966 (ATLAS 2) - A study evaluating the efficacy, safety, and tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine administered every 4 or 8 weeks in Virologically Suppressed HIV-1-infected adults.

Read More

Top of Page

GS-US-380-1490

...

A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults

Read More

Top of Page